Immunex regulatory update

The FDA's Oncologics Drugs Advisory Committee (ODAC) will review the data on Novantrone (mitoxantrone) for advanced prostate cancer on Sept. 11. IMNX submitted a supplemental NDA to the FDA in May. I...